Published in

American Society of Hematology, Blood, 20(123), p. 3059-3060, 2014

DOI: 10.1182/blood-2014-04-565267

Links

Tools

Export citation

Search in Google Scholar

Time has come for immunotherapy in PTCL

Journal article published in 2014 by Emmanuel Bachy ORCID, Bertrand Coiffier ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

In this issue of Blood, Horwitz et al present encouraging results of a phase 2 study assessing the efficacy of the antibody-drug conjugate (ADC) brentuximab vedotin (BV) in relapsed/refractory peripheral T cell lymphoma (PTCL).